Atlas: Adjuvant Tamoxifen Longer Against Shorter.
Annual rept. 1 Oct 96-30 Sep 97
OXFORD UNIV (UNITED KINGDOM)
Pagination or Media Count:
Worldwide, more than 1 million women with early breast cancer take adjuvant tamoxifen. However, there is uncertainty about the optimal duration of treatment. ATLAS is a major international trial which will help to assess this optimal duration reliably. If ATLAS demonstrates an additional advantage from longer treatment, then several thousands of deaths could be avoided each year if women are treated accordingly. The ATLAS collaboration continues to achieve its interim and overall objectives. Since 1 October 1995, the infrastructure for the trial has been established in several hundred hospitals in more than 20 countries worldwide collaborators meetings have been organized in most countries free tamoxifen has been negotiated, funding for its supply and distribution secured, and 2 cycles of tamoxifen have already been distributed by 11097 232 hospitals had ethical approval, with the remaining hospitals in the process of obtaining approval randomization had started in 146 hospitals, with about 1600 patients already randomized. The first annual follow-up took place in January 1997 on all patients randomized in the study. The independent Data Monitoring Committee had its second meeting in March 1997 and endorsed the continuing importance of ATLAS, including its design and implementation. The first meeting of the Steering Committee was held in Oxford in September 1997, and ATLAS continues to have a high profile at important international breast cancer meetings.
- Anatomy and Physiology
- Medicine and Medical Research